Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT00349336
Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 155
- Registration Number
- NCT00337493
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00337701
A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT00337649
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 736
- Registration Number
- NCT00333775
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT00327535
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 142
- Registration Number
- NCT00326963
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 605
- Registration Number
- NCT00321919
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 259
- Registration Number
- NCT00316758
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 374
- Registration Number
- NCT00316771
© Copyright 2024. All Rights Reserved by MedPath